Fennec Pharmaceuticals Inc. FENC
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Fennec Pharmaceuticals Inc. (FENC) is a healthcare company listed in the US with a market value of about $410M. In the twelve months to September 30, 2026 it had revenue of $66M and net income of $2M, a net margin of 3.1%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 387.3, 5-year revenue growth of 205% a year, a 5-year average ROIC of -39%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 104% above the current price.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $170000 in 2020 to $45M in 2025, growth of about 204.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 1% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66M | $45M | $48M | $21M | $2M | — | $170000 | $0 | $0 | $0 | $0 |
| Net income | $2M | -$10M | -$436000 | -$16M | -$24M | -$17M | -$18M | -$13M | -$10M | -$7M | -$3M |
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | $0.02 | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 | $-0.00 | $-0.64 | $-0.52 | $-0.47 | $-0.22 |
| Net margin | 3.1% | -21.8% | -0.9% | -75.5% | -1544.9% | — | -10652.4% | — | — | — | — |
| ROIC | — | -14.0% | 15.1% | -52.2% | -79.9% | -65.5% | -48.6% | -86.5% | -38.6% | -26.0% | -80.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $17.20, 48% above the current price; targets range from $16.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $0.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Fennec Pharmaceuticals’s P/E ratio?
About 387.3, based on the last twelve months of diluted earnings per share (forward P/E about 15.4).
Is Fennec Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 104% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Fennec Pharmaceuticals pay a dividend?
Not currently.
Is Fennec Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Fennec Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.